Advertisement
Research Article| Volume 16, ISSUE 2, P493-505, June 1996

Prevention of Liver Cancer and Cirrhosis by Vaccines

  • Alfred M. Prince
    Correspondence
    Address reprint requests to: Alfred M. Prince, MD, New York Blood Center, 310 East 67th Street, New York, NY 10021
    Affiliations
    From the Lindsley F. Kimball Research Institute of the New York Blood Center, New York, New York
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30281-6
Prevention of Liver Cancer and Cirrhosis by Vaccines
Previous ArticleInterferon and Other Therapies for Hepatitis B and Hepatitis C Infections
Next ArticleIndex
      This paper is only available as a PDF. To read, Please Download here.
      Existing vaccines for hepatitis B virus (HBV) are described, and their advantages and efficacies are compared. The possible advantages of including PreS determinants are discussed. Use of HBV vaccines, although increasing, remains at a disappointing level if worldwide eradication of HBV-associated chronic liver disease is to be achieved. The evolution of vaccine-resistant HBV strains is discussed. Vaccines need to be developed for hepatitis C virus as well, and impediments and solutions to their development are reviewed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Alper C.A.
        • Kruskall M.S.
        • Marcus-Bagley D.
        Genetic prediction of nonresponse to hepatitis B vaccine.
        N Engl J Med. 1989; 321: 708
        • Beasley R.P.
        • Huang L-Y
        • Lin C.C.
        • et al.
        Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan.
        Lancet. 1981; 2: 1129
        • Ambrosch F.
        • Widermann G.
        • Andre F.E.
        • et al.
        Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine.
        J Med Virol. 1994; 44: 452
        • Carman W.F.
        • Zanetti A.R.
        • Karayiannis P.
        • et al.
        Vaccine-induced escape mutant of hepatitis B virus.
        Lancet. 1990; 336: 325
        • Chiou S-S
        • Yamauchi K.
        • Nakanishi T.
        Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals.
        Immunology. 1988; 64: 545
        • Choo Q-L
        • Kuo G.
        • Ralston R.
        • et al.
        Vaccination of chimpanzees against infection by the hepatitis C virus.
        Proc Natl Acad Sei USA. 1994; 91: 1294
        • Coursaget P.
        • Yvonnet B.
        • Relyveld E.H.
        • et al.
        Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccine in a simplified immunization program: Immune response to diphtheria toxoid, pertussis, and hepatitis B surface antigen.
        Infect Immun. 1986; 51: 784
        • De Wilde M.
        • Cabezon T.
        • Harford N.
        Production in yeast of hepatitis B surface antigen by rDNA technology.
        Dev Biol Stand. 1985; 59: 99
        • Dienstag J.L.
        • Stevens C.E.
        • Bhan A.K.
        • et al.
        Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen.
        Ann Intern Med. 1982; 96: 575
        • Dunsford H.A.
        • Sell S.
        • Chisari F.V.
        Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice.
        Cancer Res. 1990; 50: 3400
        • Emini E.A.
        • Larson V.
        • Eichberg
        • et al.
        Protective effect of a synthetic peptide comprising the complete pre-S2 region of the hepatitis B virus surface protein.
        J Med Virol. 1989; 28: 7
        • Feitelson M.
        Hepatitis B virus infection and primary hepatocellular carcinoma.
        Clin Microbiol Rev. 1992; 5: 275
        • Feitelson M.A.
        Biology of disease. Biology of hepatitis B virus variants.
        Lab Invest. 1994; 71: 324
        • Feitelson M.A.
        • Zhu M.
        • Duan L-X
        • et al.
        Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma.
        Oncogene. 1993; 8: 1109
        • Foulds L.
        The natural history of cancer.
        J Chronic Dis. 1958; 8: 2
        • Francis D.P.
        • Feorino P.M.
        • McDougal S.
        The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture.
        JAMA. 1986; 256: 869
        • Fynan E.F.
        • Webster R.G.
        • Fuller D.H.
        • et al.
        DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations.
        Proc Natl Acad Sei USA. 1993; 90: 11478
        • Goritsas C.P.
        • Athanasiadou A.
        • Arvaniti A.
        • et al.
        The leading role of hepatitis B and viruses as risk factors for the development of hepatocellular carcinoma. A case control study.
        J Clin Gastroenterol. 1995; 20: 220
        • Hadler S.C.
        • Francis D.P.
        • Maynard J.E.
        • et al.
        Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.
        N Engl J Med. 1986; 315: 209
        • Hadziyannis S.
        • Tabor E.
        • Kaklamani E.
        • et al.
        A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma.
        Int J Cancer. 1995; 60: 627
        • Hepatitis B virus
        A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination.
        MMWR. 1991; 40: 1
        • Hijikata M.
        • Shimizu Y.K.
        • Kato H.
        • et al.
        Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes.
        J Virol. 1993; 67: 1953
        • Hilleman M.R.
        • Buynak E.B.
        • Roehm R.R.
        • et al.
        Purified and inactivated human hepatitis B vaccine: Progress report.
        Am J Med Sei. 1975; 270: 401
        • Itoh Y.
        • Takai E.
        • Ohnuma H.
        • et al.
        A synthetic peptide vaccine involving the product of the pre-S2 region of hepatitis B virus DNA: Protection efficacy in chimpanzees.
        Proc Natl Acad Sei USA. 1986; 83: 9174
        • Iwarson S.
        • Tabor E.
        • Thomas H.C.
        • et al.
        Protection against hepatitis B virus infection by immunization with hepatitis B c-antigen.
        Gastroenterology. 1985; 88: 763
        • Kaneko S.
        • Unoura M.
        • Takeuchi M.
        The role of hepatocellular carcinoma in Japan.
        Intervirology. 1994; 37: 108
        • Kew M.C.
        Hepatitis C virus and hepatocellular carcinoma.
        FEMS Microbiol Rev. 1994; 14: 211
        • Kiyosawa K.
        • Furuta S.
        Hepatitis C virus and hepatocellular carcinoma.
        Curr Stud Hematol Blood Transf. 1994; 61: 98
        • Krugman S.
        • Giles J.P.
        • Hammond J.
        Viral hepatitis, type B (MS-2 strain). Studies on active immunization.
        JAMA. 1971; 217: 41
        • Krugman S.
        • Davidson M.
        Hepatitis B vaccine: Prospects for duration of immunity.
        Yale J Biol Med. 1987; 60: 333
        • Kurtz J.B.
        • Alder M.J.
        • May on-White R.T.
        Plasma-derived versus recombinant hepatitis B vaccines.
        Lancet. 1989; 1: 451
        • Liang T.J.
        • Jeffers L.J.
        • Reddy K.R.
        • et al.
        Viral pathogenesis of hepatocellular carcinoma in the United States.
        Hepatology. 1993; 18: 1326
        • Lieming D.
        • Mintai Z.
        • Yinfu W.
        • et al.
        A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates.
        Clin Infect Dis. 1993; 17: 475
        • Lübeck M.D.
        • Davis A.R.
        • Chengalvala M.
        • et al.
        Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus.
        Proc Natl Acad Sei USA. 1989; 86: 6763
        • McAleer W.J.
        • Buynak E.B.
        • Maigetter R.Z.
        Human hepatitis B vaccine from recombinant yeast.
        Nature. 1984; 307: 178
        • McMahon G.
        • Ehrlich P.H.
        • Moustafa Z.A.
        • et al.
        Genetic alterations in the gene encoding the major HbsAg: DNA and immunological analysis of recurrent HbsAg derived from monoclonal antibody-treated liver transplant patients.
        Hepatology. 1992; 15: 757
        • Metz T.
        • Smitz J.
        • Ngendahayo P.
        • et al.
        Hepatitis C virus infection in African patients with liver cirrhosis or primary hepatocellular carcinoma.
        Scand J Gastroenterol. 1993; 28: 331
        • Milich D.R.
        • Thronton G.B.
        • Neurath A.R.
        • et al.
        Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.
        Science. 1985; 228: 1195
        • Moss B.
        • Smith G.L.
        • Gerin J.L.
        • et al.
        Live recombinant vaccinia virus protects chimpanzees against hepatitis B.
        Nature. 1984; 311: 67
        • Moyes C.D.
        • Milne A.
        • Kimitrakakis M.
        Very-low-dose hepatitis B vaccine in newborn infants: An economic option for control in endemic areas.
        Lancet. 1987; 1: 29
        • Murray K.
        • Bruce S.A.
        • Wingfield P.
        • et al.
        Protective immunization against hepatitis B virus infection by immunization with an internal antigen of the virus.
        J Med Virol. 1987; 23: 101
        • Murray K.
        • Bruce S.A.
        • Hinnen A.
        • et al.
        Hepatitis B virus antigens made in microbial cells immunize against viral infection.
        EMBO J. 1984; 3: 645
        • Okuda K.
        • Fujimoto I.
        • Hanai A.
        • et al.
        Changing incidence of hepatocellular carcinoma in Japan.
        Cancer Res. 1987; 47: 4967
        • Panda S.K.
        • Ramesh R.
        • Rao K.V.S.
        Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants.
        J Med Virol. 1991; 35: 297
        • Paoletti E.
        • Lipinskas B.R.
        • Samsonoff C.
        • et al.
        Construction of live vaccines using genetically engineered poxviruses: Biological activity of vaccinia virus recombinants expression the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
        Proc Natl Acad Sei USA. 1984; 81: 193
        • Parkin D.M.
        • Stjernsward T.
        • Muir C.S.
        Estimates of the worldwide frequency of twelve major cancers.
        Bull World Health Organ. 1984; 62: 163
        • Payet M.
        • Camain R.
        • Pene P.
        Le cancer primitif du foie, etude critique a propos de 240 cas.
        Rev Int Hepatol. 1956; 4: 1
        • Prince A.M.
        • Brotman B.
        • Huima T.
        • et al.
        Immunity in hepatitis C infection.
        J Infect Dis. 1992; 165: 438
        • Prince A.M.
        Challenges for development of hepatitis C virus vaccines.
        FEMS Microbiol Rev. 1994; 14: 273
        • Prince A.M.
        The role of viruses in chronic liver disease in man and animals.
        IARC Sei Publ. 1971; 1: 51-57
        • Prince A.M.
        • Szmuness W.
        • Michon J.
        • et al.
        A case/control study of the association between primary liver cancer and hepatitis B infection in Senegal.
        Inti J Cancer. 1975; 16: 376
        • Prince A.M.
        • Brotman B.
        • Purcell R.H.
        • et al.
        A final report on safety and immunogenicity of a bivalent aqueous subunit HBV vaccine.
        J Med Virol. 1985; 15: 399
        • Prince A.M.
        • Vnek J.
        • Brotman B.
        An affordable multideterminant plasma derived hepatitis B virus vaccine.
        IARC Sei Publ. 1984; 63: 355-372
        • Prince A.M.
        • Szmuness W.
        • Hargrove R.L.
        • et al.
        The serum hepatitis virus specific antigen (SH): A status report.
        Perspect Virol. 1971; 7: 241
        • Qiao Z-K
        • Halliday M.L.
        • Rankin J.G.
        • et al.
        Relationship between hepatitis B surface antigen prevalence, per capita alcohol consumption and primary liver cancer death rate in 30 countries.
        J Clin Epidemiol. 1988; 41: 787
        • Redfield R.R.
        • Innis B.L.
        • Scott R.M.
        Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy.
        JAMA. 1985; 254: 3203
        • Ronish R.H.
        • Diniega B.M.
        • Kelley P.W.
        Immunogenicity achieved by the intradermal hepatitis B vaccination programme for US Army soldiers in Korea.
        Vaccine. 1991; 9: 364
        • Ruiz J.
        • Sangro B.
        • Cuende J.I.
        • et al.
        Hepatitis B and C viral infections in patients with hepatocellular carcinoma.
        Hepatology. 1992; 16: 637
        • Sakamura D.
        • Furukawa
        • Takegami T.
        Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells.
        J Virol. 1995; 69: 3893
        • Sakamoto M.
        • Hirohashi S.
        • Tsuda E.
        • et al.
        Increasing incidence of hepatocellular carcinoma possibly associated with non-A, non-B hepatitis in Japan, disclosed by hepatitis B virus DNA analysis of surgically resected cases.
        Cancer Res. 1988; 48: 7294
        • Schodel F.
        • Kelly S.M.
        • Peterson D.L.
        • et al.
        Hybrid hepatitis B virus core-Pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.
        Infect Immun. 1994; 62: 1669
        • Schodel F.
        • Neckermann G.
        • Peterson D.
        • et al.
        Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection.
        Vaccine. 1993; 11: 624
        • Soulie J.C.
        • Devillier P.
        • Santarelli J.
        • et al.
        Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
        Vaccine. 1991; 9: 545
        • Steiner P.E.
        • Davies J.N.
        Cirrhosis and primary liver cancer in Uganda Africans.
        Br J Cancer. 1957; 11: 523
        • Stevens C.E.
        • Taylor P.E.
        • Tong M.J.
        Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission.
        JAMA. 1987; 257: 2612
        • Stroffolini T.
        • Chiaramonte M.
        • Tiribelli C.
        • et al.
        Hepatitis C virus infection, HBsAg carrier state and hepatocellular carcinoma: Relative risk and population attributable risk from a case-control study in Italy.
        J Hepatol. 1992; 16: 360
        • Struve J.
        • Aronsson B.
        • Frenning B.
        Seroconversion after additional vaccine doses to nonresponders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine.
        Scand J Infect Dis. 1994; 26: 468
      68. Suboptimal response to hepatitis B vaccine given by injection into the buttock.
        MMWR. 1985; 34: 105
        • Szmuness W.
        • Stevens C.E.
        • Zhang E.A.
        • et al.
        A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report.
        Hepatology. 1981; 1: 377
        • Tabor E.
        • Buynak E.
        • Smallwood L.A.
        • et al.
        Inactivation of hepatitis B virus by three methods: Treatment with pepsin, urea, or formalin.
        J Med Virol. 1983; 11: 1
        • Tan K.L.
        • Goh K.T.
        • Oon C.J.
        Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization.
        JAMA. 1994; 271: 859
        • Tanaka H.
        • Hiyama T.
        • Tsukuma H.
        • et al.
        Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: Statistical estimations from cross-sectional data.
        Jpn J Cancer Res. 1994; 85: 485
        • Thanavala Y.
        • Yang Y-F
        • Lyons P.
        • et al.
        Immunogenicity of transgenic plant-derived hepatitis B surface antigen.
        Proc Natl Acad Sei USA. 1995; 92: 3358
        • Tron F.
        • Degos F.
        • Brechot C.
        • et al.
        Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and preS2 sequences.
        J Infect Dis. 1989; 160: 199
        • Ulmer J.B.
        • Donnelly J.J.
        • Parker S.E.
        • et al.
        Heterologous protection against influenza by injection of DNA encoding a viral protein.
        Science. 1993; 259: 1745
        • Weiner A.J.
        • Brauer M.
        • Rosenblatt M.J.
        • et al.
        Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NSI proteins and the pestivirus envelope glycoproteins.
        Virology. 1991; 180: 842
        • Wong C.W.
        • Ip H.M.H.
        • Reesink H.W.
        • et al.
        Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis B immunoglobulin.
        Lancet. 1984; 1: 921
        • Xiang Z.Q.
        • Spitalnik S.
        • Tran M.
        • et al.
        Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.
        Virology. 1994; 199: 132
        • Xu Z-Y
        • Liu C-B
        • Francis D.P.
        • et al.
        Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: Preliminary report of a randomized, double-blind placebo-controlled and comparative trial.
        Pediatrics. 1985; 76: 713
        • Yu M-W
        • You S-L
        • Chang A-S
        • et al.
        Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan.
        Cancer Res. 1991; 51: 5621

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30281-6

      Copyright

      © 1996 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX